ArticleThe Lancet regional health. Western Pacific2026
Asymptomatic tuberculosis in Japan: a 15-year national surveillance study, 2008-2022.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asymptomatic tuberculosis (TB), defined as active TB without reported symptoms, remains poorly characterised. We assessed long-term trends, factors associated with asymptomatic diagnosis, and treatment outcomes of asymptomatic TB in Japan using nationwide surveillance data with widespread chest radiographic screening. Methods: We analysed bacteriologically confirmed pulmonary TB cases reported to the Japan Tuberculosis Surveillance System between 2008 and 2022. Patients were classified as asymptomatic, respiratory symptomatic, or non-respiratory symptomatic TB. Trends in symptom status were assessed. Factors associated with asymptomatic diagnosis and mortality during treatment were evaluated using modified Poisson regression with cluster-robust standard errors among cases notified during 2017-2022, when key covariates were consistently available. Findings: Among 141,481 pulmonary TB cases, 20.2% were asymptomatic, 61.3% had respiratory symptoms, and 18.5% had non-respiratory symptoms. Over time, the proportion of asymptomatic TB increased slightly, remaining around one-fifth of all pulmonary TB cases and 12-15% of cases with smear-positive or cavitary disease. Among asymptomatic patients, 34.1% were smear positive and 20.3% had cavitary disease. In multivariable analysis, asymptomatic TB was more common in younger groups, those in employment or education, and those with previous TB treatment. Mortality during treatment was lower in asymptomatic TB (adjusted risk ratio 0.57, 95% CI 0.54-0.60) than in respiratory symptomatic TB. Interpretation: Asymptomatic TB represents a substantial and persistent component of the TB burden in Japan, including potentially infectious cases. Reliance on symptom-based case detection alone may miss a considerable proportion of TB, supporting the need for targeted screening and earlier diagnosis. Funding: Research Institute of Tuberculosis (general research funds).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.